The Royal College of Ophthalmologists. National Ophthalmology Database Audit | The second report of age-related macular degeneration audit (AMD): patients starting treatment for neovascular AMD in the 2021 NHS year (01 April 2021 to 31 March 2022). March 2024; London, UK: The Royal College of Ophthalmologists. Accessed 6 February 2025. https://nodaudit.org.uk/sites/default/files/2024-05/NOD%20Audit%20AMD%20Full%20Annual%20Report%202024_0.pdf.
The Royal College of Ophthalmologists. Census Report | Facing workforce shortages and backlogs in the aftermath of COVID-19: the 2022 census of the ophthalmology consultant, trainee and SAS workforce. March 2023; London, UK: The Royal College of Ophthalmologists. Accessed 6 February 2025. https://www.rcophth.ac.uk/wp-content/uploads/2023/03/2022-Ophthalmology-census-Facing-workforce-shortages-and-backlogs-in-the-aftermath-of-COVID-19.pdf.
The Royal College of Ophthalmologists. Commissioning Guidance | Age related macular degeneration services: recommendations. May 2024; London, UK: The Royal College of Ophthalmologists. Accessed 6 February 2025. https://www.rcophth.ac.uk/wp-content/uploads/2021/08/AMD-Services-Commissioning-Guidance-Recommendtions.pdf.
Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PJ, Balaskas K, et al. Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye. 2022;36:1373–78.
Google Scholar
Sivaprasad S, Bailey C, Downey L, Gilbert R, Gale R, Kotagiri A, et al. Real-world service costs for neovascular-AMD clinics in the United Kingdom: structured literature review and scenario analysis. Curr Med Res Opin. 2024;40:1221–33.
Google Scholar
Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye. 2019;33:1–21.
Google Scholar
Lanzetta P, Korobelnik J-F, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141–52.
Google Scholar
Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration: 96-week results from the randomized phase 3 PULSAR trial. Ophthalmology. 2025. https://doi.org/10.1016/j.ophtha.2025.08.022.
Google Scholar
Bayer plc. Eylea 114.3 mg/ml solution for injection in pre-filled syringe – summary of product characteristics; updated 9 September 2024. Bayer plc: Reading, UK.
Bayer plc. Eylea 40 mg/ml solution for injection in a vial – summary of product characteristics; updated 11 September 2023. Bayer plc: Reading, UK.
Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye. 2023;37:6–16.
Google Scholar
NHS England. Commissioning guidance: medical retinal treatment pathway in wet age-related macular degeneration 2025. https://uk-oa.co.uk/wp-content/uploads/2025/08/Commissioning-Guidance-Medical-Retinal-Treatment-Pathway-in-Wet-Age-related-Macular-Degenerati-1.pdf.
Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR – a randomized controlled trial. Adv Ther. 2020;37:1173–87.
Google Scholar
Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration – the ARIES study: a randomized clinical trial. Retina. 2021;41:1911–20.
Google Scholar
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.
Google Scholar
Bailey C, Cackett P, Kotagiri A, Mahmood S, Minos E, Narendran N, et al. Practical implementation of a q4–q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: updated guidance from a UK expert panel. Eye. 2023;37:1916–21.
Google Scholar
Ross AH, Downey L, Devonport H, Gale RP, Kotagiri A, Mahmood S, et al. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye. 2020;34:1825–34.
Google Scholar
Downey L, Sivaprasad S, Chhabra R, Bailey C, Chakrabarti S, Elsherbiny S, et al. Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists. Eye. 2024;38:3077–86.
Google Scholar
Narendran N, Bailey C, Downey L, Gale R, Kotagiri A, Pearce I, et al. Expert panel consensus for optimizing outcomes in neovascular age-related macular degeneration in the context of suboptimal response to a biosimilar: the role of aflibercept. Clin Ophthalmol. 2024;18:3133–42.
Google Scholar
The Royal College of Ophthalmologists. Intravitreal injection therapy. Accessed 6 February 2025. https://www.rcophth.ac.uk/wp-content/uploads/2022/02/Intravitreal-Injection-Therapy-August-2018-1.pdf.
Uzzan J, Mapani A, Cox O, Bagijn M, Saffar I. Clinical outcomes and experiences with prefilled syringes versus vials for intravitreal administration of anti-VEGF treatments: a systematic review. Ophthalmol Ther. 2024;13:2445–65.
Google Scholar
Schmidt-Ott U, Fitzpatrick S, Hasanbasic Z, Leal S, Morgan-Warren P, Zhang X, et al. Reported rates of intraocular inflammation with intravitreal aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022. Clin Ophthalmol. 2023;17:385–90.
Google Scholar
Yamamoto M, Hirayama K, Kyo A, Kinari G, Kojima Y, Kohno T, et al. Immediate and short-term intraocular pressure changes following intravitreal injection and associated factors. J Clin Med. 2025;14:4821.
Google Scholar
Schmidt-Erfurth U, Mulyukov Z, Gerendas BS, Reiter GS, Lorand D, Weissgerber G, et al. Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis. Eye. 2023;37:1160–69.
Google Scholar
Yu S, Jones IL, Maunz A, Bachmeier I, Albrecht T, Ebneter A, et al. Artificial intelligence-based analysis of retinal fluid volume dynamics in neovascular age-related macular degeneration and association with vision and atrophy. Eye. 2025;39:154–61.
Google Scholar
Cho SC, Park KH, Park SJ, Joo K, Woo SJ. Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5. Front Med. 2023;10:1204026.
Google Scholar
y, oishi a, maekawa y, tsuiki e, machida a, kurihara j, et al. Recurrence of neovascular age-related macular degeneration after session of trade and extend regimen. Sciently scientists rep. 2022;12:14768.
Google Scholar
General Medical Council. Decision making and consent. Last update: 13 December 2024. https://www.gmc-uk.org/professional-standards/the-professional-standards/decision-making-and-consent.
National Institute for Health and Care Excellence (NICE). NG82: Age-related macular degeneration. https://www.nice.org.uk/guidance/ng82.
Gale RP, Airody A, Sivaprasad S, Hanson RLW, Allgar V, McKibbin M, et al. Improved structure and function in early-detected second-eye neovascular age-related macular degeneration: FASBAT/early detection of neovascular age-related macular degeneration report 1. Ophthalmol Retina. 2024;8:545–52.
Google Scholar
Musadiq M, Musadiq M, Latif F, Ng B, Azzopardi M, Gilead N, et al. Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life. 2025;15:903.
Google Scholar
Hosoda S, Sakurada Y, Fukuda Y, Kotoda Y, Kikushima W, Kashiwagi K. Short-term outcomes of three consecutive monthly loading administrations of aflibercept 8 mg for treatment-naive exudative age-related macular degeneration. Pharmaceuticals. 2025;18:438.
Google Scholar
Abu Ishkheidem I, Inci E, Breimer M, Silfversward ST, Zetterberg M, Gronlund MA. Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration. Acta Ophthalmol. 2025. https://doi.org/10.1111/aos.17590.
Palm C, Zweifel SA, Gabathuler F, Cozzi M, Fasler K. Efficacy of aflibercept 8 mg in pretreated age-related macular degeneration. J Clin Med. 2025;14:4900.
Google Scholar
Sambhara D, Vakharia P, Eichenbaum DA. Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol. 2025;10:e002091.
Google Scholar
Momenaei B, Yonekawa Y, Abril P, McCullough R, Abbey AM. Outcomes of intravitreal aflibercept 8 mg in eyes with neovascular age-related macular degeneration previously treated with faricimab. Ophthalmic Surg Lasers Imaging Retina. 2025;56:206–11.
Google Scholar
Nowroozzadeh MH, Hajipourkhorasani M. Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: A pharmacovigilance analysis of the FAERS database. Ocul Immunol Inflamm. 2025;33:1056–8.
Google Scholar
Matsumoto H, Hoshino J, Numaga S, Asatori Y, Akiyama H. Loading phase outcomes of intravitreal aflibercept 8 mg for treatment-naive neovascular age-related macular degeneration. Jpn J Ophthalmol. 2025;69:911–7.
Google Scholar
LU X, you are K, KUGAI m, Nochi y, Yamamoto a, ko r, et al. Comparison of Intraocular Pressure Elevation Following Intravitreal injection of 70 micromcrol fliercept 8 mg. Jpn J Ophthalmol. 2025;69:926–3
Google Scholar
Gartaganis P, Khamis N, Hamoud Bedan A, Driouich Z, Ashraf MO, Abucar Osman S, et al. A comparative assessment of intraocular pressure changes after aflibercept 8 mg and faricimab-svoa intravitreal injections in wet age-related macular degeneration. Cureus. 2025;17:e88617.
Google Scholar
Chakravarthy U, Armendariz BG, Fauser S. 15 years of anti-VEGF treatment for nAMD: success or failure or something in between? Eye. 2022;36:2232–33.
Google Scholar
Quist SW, Nab H, Postma M, Amarakoon S, van Asten F, Freriks R. A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands. Graefes Arch Clin Exp Ophthalmol. 2025;263:327–45.
Google Scholar
NHS England. Operational note: updated commissioning recommendations for medical retinal vascular medicines following the national procurement for ranibizumab biosimilars. Accessed 6 February 2025.
